Overview

A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease

Status:
Completed
Trial end date:
2013-08-20
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled Phase 2B study to evaluate the efficacy and safety of Larazotide Acetate in the treatment of patients with celiac disease who have persistent symptoms despite being on a gluten-free diet.
Phase:
Phase 2
Details
Lead Sponsor:
9 Meters Biopharma, Inc.
Alba Therapeutics
Collaborator:
Teva Pharmaceuticals USA